title: Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
abstract: Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART). Between July 2007 and October 2010, 27 consecutive HIV-u-HCC patients were treated with sorafenib and concomitant HAART within the Gruppo Italiano Cooperativo AIDS e Tumori (GICAT). Three patients achieved a partial response, 12 achieved a stable disease, and 12 showed progression. The median time to progression and overall survival was 5.1 (range 0.5-13.3) and 12.8 (range 1.1-23.5) months, respectively. Grades 3-4 toxicities included diarrhea (four patients, 14.8%), hypertension (three patients, 11%), and hand-and-foot skin reaction (four patients, 14.9%). Most drug-related side effects were low grade and manageable. This retrospective study shows favorable survival data among HIV-u-HCC patients treated with sorafenib together with a reasonable safety profile.
authors.affiliation: Department of Medical Oncology, National Cancer Institute--IRCCS, Aviano (PN), Italy. mberretta@cro.it
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Berretta
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Di Benedetto
authors.forename: Luigino
authors.initials: L
authors.lastname: Dal Maso
authors.forename: Bruno
authors.initials: B
authors.lastname: Cacopardo
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Nasti
authors.forename: Gaetano
authors.initials: G
authors.lastname: Facchini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bearz
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Elisa
authors.initials: E
authors.lastname: Garlassi
authors.forename: Valli
authors.initials: V
authors.lastname: De Re
authors.forename: Francesco
authors.initials: F
authors.lastname: Fiorica
authors.forename: Arben
authors.initials: A
authors.lastname: Lleshi
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000821:virology*; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib